TB treatment: latest news

TB treatment resources

TB treatment features

TB treatment in your own words

TB treatment news from aidsmap

More news

TB treatment news selected from other sources

  • Newly identified marker helps predict tuberculosis complications in HIV patients

    An NIAID study suggests that the increased frequency of an immune cell called CD14++CD16- monocyte is a strong indicator that a patient with HIV and tuberculosis (TB) may develop immune reconstitution inflammatory syndrome (IRIS).

    16 October 2014 | National Institute of Allergy and Infectious Diseases (NIAID) press release
  • In HIV/TB coinfection, initiate antiretroviral therapy early

    Earlier initiation of antiretroviral therapy (ART) significantly lowered mortality in patients with HIV and tuberculosis (TB) co-infection, despite a higher incidence of immune reconstitution inflammatory syndrome (IRIS), according to data presented at 2014 IDWeek.

    16 October 2014 | Monthly Prescribing Reference (MPR)
  • What does new drug PaMZ mean for TB and HIV treatment?

    The development of PaMZ has been hailed as a breakthrough. But what do the experts think?

    02 September 2014 | The Guardian
  • Acquired rifampicin resistance more likely in HIV-coinfected patients

    Patients with HIV and tuberculosis were more likely to develop acquired rifampicin resistance when treated with a thrice-weekly tuberculosis treatment compared with patients not coinfected with HIV, according to researchers from the National Institute for Research in Tuberculosis in India. The rate of bacteriologic failure was 4% among patients without HIV. Among patients with HIV, the rates were 9% for those not receiving ART and 5% for those receiving ART.

    02 September 2014 | Healio
  • From Rhetoric to Reality: An Analysis of Efforts to Scale Up The Response to TB-HIV

    A new research report from ACTION global health shows that joint TB-HIV activities are neglected by HIV programs and overwhelmingly carried out by TB programs, and that global guidelines to address TB-HIV have not been prioritized by leading donors and affected countries.

    22 July 2014 | ACTION
  • HIV, HCV and TB Pipeline Report

    Drugs, diagnostics, vaccines, preventive technologies, research towards a cure, and immune-based and gene therapies in development.

    21 July 2014 | Treatment Action Group & i-Base
  • Apathy in TB fight: The Economist Intelligence Unit

    A new report on tuberculosis calls for raising the profile of TB, fight apathy and lack of compelling ambition in addressing the disease.

    04 July 2014 | Stop TB Partnership
  • An activist's guide to TB drugs

    TB treatment must be shorter, simpler, less toxic, and more tolerable and affordable. Activists can contribute to the development and uptake of improved TB treatment by calling attention to research, quality of medications, and access priorities.

    04 June 2014 | TAG
  • In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

    Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

    02 June 2014 | Medscape
  • TB drug approvals, distribution deal inches options forward, but MDR TB treatment access still uncertain where needed most

    Last week’s important developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility.

    14 May 2014 | Science Speaks
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also